肝癌经导管栓塞化疗生存三年以上48例分析

TKANSCATHETER CHEMOEMBOLIZATION FOR PRIMARY HEPATIC CARCINOMA A CLINICAL ANALYSIS OF 48 CASES WITH SURVIAL PERIOD LONGER THAN THREE YEARS

对２２５例原发性肝癌行ＬＰ—ＴＡＥ治疗，生存３年以上４８例，占同期治疗病人的２１．３３％，其中包括生存４年以上２５例（１１．１１％）及生存５年以上６例（６．４５％）。对生存３后以上的４８例综合分析，认为：病程分期、肝功能及其治疗后的改变、肝硬化、肿瘤生长方式、肿瘤大小及术后缩小程度、术后ＡＦＰ的改变、ＬＰ—ＴＡＥ治疗方式及质量和是否伴有肝内、外转移等因素对肝癌ＬＰ—ＴＡＥ后的长期生存有影响。

l. 33)cases in 225 cases of primary hepatic carcinoma treatd with lipiodol transcatheter arterial embolization(LP TAE)have survived more than 3 years,among them,25(1 11%)survived more than 4 years and6(6.45%)more than 5 years. we believed the factors that significantly affected long term survival included clinical staging, hepatic function and its change after treatment, cirrhosis, growing pattern of tumor, tumor size and its shrinking extent after operation,chang of AFP after operation pattern and quality of LP TAE treatment, and intra or and extrahepatic metastasis.